IRVINE, Calif., May 16, 2017 /PRNewswire/ -- Pharmadax Inc., a pharmaceutical company based in New Taipei City,
Seroquel XR® is a once-daily tablet indicated for the treatment of schizophrenia; acute depressive episodes in bipolar disorder; acute manic or mixed episodes in bipolar disorder alone or with lithium or divalproex; and adjunctive therapy to antidepressants for patients with major depressive disorder (MDD).
According to IMS Health data, U.S. sales of Seroquel XR® and generic equivalents for the 5 strengths to be marketed by TruPharma LLC were approximately $1.34 billion for the 12 months ended December 31, 2016.
Yipin Huang, Chairman of Pharmadax Inc., stated: "We are very excited to receive approval of our first controlled-release product, and second overall approval by the US FDA. Launching this product in the US market is a major milestone for Pharmadax. Leveraging on our unique business model and technology platform, we look forward to providing more affordable and high quality complex dosage forms to the American public."
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pharmadax-receives-fda-approval-for-a-generic-version-of-seroquel-xr-300457977.html
SOURCE Pharmadax Inc.
Subscribe to our Free Newsletters!
Hand hygiene is a simple and affordable technique to prevent infections.
Erythropoietin is a hormone secreted by kidneys in response to low oxygen levels in tissues ...
Local anesthesia is a type of anesthesia generally used to block pain sensation only in a specific ...View All